CORBUS PHARMACEUTICALS HOLDI (CRBP)

US21833P3010 - Common Stock

39.43  +3.86 (+10.85%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CORBUS PHARMACEUTICALS HOLDI

NASDAQ:CRBP (3/28/2024, 12:47:23 PM)

39.43

+3.86 (+10.85%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap413.62M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CRBP Daily chart

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company is headquartered in Norwood, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2014-10-24. The firm is engaged in developing and commercializing therapeutics for autoimmunity, fibrosis, and cancer. Its internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. The company has developed CRB-913, a second-generation cannabinoid receptor type 1 (CB1) inverse agonist designed to treat obesity and related metabolic diseases. The CRB-913 program is in the pre-clinical-stage. The company also includes Lenabasum, which is a novel, synthetic, oral molecule that selectively activates cannabinoid receptor type 2 (CB2) for the treatment of inflammation and fibrosis. Its subsidiaries include Corbus Pharmaceuticals, Inc., Corbus International Limited and Corbus Pharmaceuticals Australia Pty Ltd.

Company Info

CORBUS PHARMACEUTICALS HOLDI

500 River Ridge Drive

Norwood MASSACHUSETTS 02062

P: 16179630103

CEO: Yuval Cohen

Employees: 33

Website: https://www.corbuspharma.com/

CRBP News

News Image16 days ago - Corbus Pharmaceuticals Holdings, Inc.Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 ...

News Image22 days ago - Corbus Pharmaceuticals Holdings, Inc.Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that...

News Imagea month ago - Corbus Pharmaceuticals Holdings, Inc.Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology...

CRBP Twits

Here you can normally see the latest stock twits on CRBP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example